Matthew D. Slein

Interaction with complement factor C1q can contribute to and improve monoclonal antibody-mediated protection against lethal HSV-1 challenge

This study shows that modifying monoclonal antibodies to interact with complement factor C1q can enhance or reduce their ability to protect against lethal HSV-1 infection in neonatal mice.

Structure-based design of soluble prefusion-stabilized herpes simplex virus type 2 glycoprotein B antigens

This study designs prefusion-stabilized HSV-2 gB antigens using structure-based methods and evaluates their immunogenicity, finding no improvement in neutralizing antibody titers compared to postfusion constructs.

Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection

The paper identifies prefusion-specific human antibodies against HSV-2 gB that neutralize both HSV-1 and HSV-2 and protect neonatal mice.

Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice

This study shows that gB-targeting antibodies protect neonatal mice from HSV infection, requiring both neutralization and Fc effector functions, with transgenerational protection achievable via AAV-mediated delivery.

Improving antibody-mediated protection against HSV infection by eliminating interactions with the viral Fc receptor gE/gI

The study shows engineered antibodies lacking Fc receptor binding improve HSV protection, suggesting vaccine strategies targeting IgG3 could enhance immunity.

Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.

This study identifies protective antibodies against Mycobacterium tuberculosis and shows that their Fc-effector function and Fab domains collaborate to restrict infection through immune cell reorganization.